Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Alzheimer's Disease

Free Subscription Articles published in J Neurol Neurosurg Psychiatry Retrieve available abstracts of 56 articles: HTML format

Single Articles

July 2024
1. MATSUOKA T, Oya N, Narumoto J, Kitani-Morii F, et al
   Reduced pineal volume may be associated with amyloid pathology and not with putative Lewy body pathology.
   J Neurol Neurosurg Psychiatry. 2024;95:791-792.
   PubMed    
   
   
   June 2024
2. DOBSON R, Patterson K, Malik R, Mandal U, et al
   Eligibility for antiamyloid treatment: preparing for disease-modifying therapies for Alzheimer's disease.
   J Neurol Neurosurg Psychiatry. 2024 Jun 11:jnnp-2024-333468.
   PubMed     Abstract available
   
   
   
3. UNDERWOOD BR
   Predicting how many people might receive treatment with new therapies for Alzheimer's disease.
   J Neurol Neurosurg Psychiatry. 2024 Jun 11:jnnp-2024-333941.
   PubMed    
   
   
   April 2024
4. KOROLOGOU-LINDEN R, Xu B, Coulthard E, Walton E, et al
   Genetics impact risk of Alzheimer's disease through mechanisms modulating structural brain morphology in late life.
   J Neurol Neurosurg Psychiatry. 2024 Apr 25:jnnp-2023-332969.
   PubMed     Abstract available
   
   
   March 2024
5. SHIR D, Corriveau-Lecavalier N, Bermudez Noguera C, Barnard L, et al
   Clinicoradiological and neuropathological evaluation of primary progressive aphasia.
   J Neurol Neurosurg Psychiatry. 2024 Mar 21:jnnp-2023-332862.
   PubMed     Abstract available
   
   
   
6. ANDERSON EL, Davies NM, Korologou-Linden R, Kivimaki M, et al
   Dementia prevention: the Mendelian randomisation perspective.
   J Neurol Neurosurg Psychiatry. 2024;95:384-390.
   PubMed     Abstract available
   
   
   January 2024
7. PATEL V, Edison P
   Cardiometabolic risk factors and neurodegeneration: a review of the mechanisms underlying diabetes, obesity and hypertension in Alzheimer's disease.
   J Neurol Neurosurg Psychiatry. 2024 Jan 30:jnnp-2023-332661.
   PubMed     Abstract available
   
   
   
8. KEUSS SE, Coath W, Cash DM, Barnes J, et al
   Rates of cortical thinning in Alzheimer's disease signature regions associate with vascular burden but not with beta-amyloid status in cognitively normal adults at age 70.
   J Neurol Neurosurg Psychiatry. 2024 Jan 10:jnnp-2023-332067.
   PubMed     Abstract available
   
   
   December 2023
9. YANG T, Xiao Y, Cheng Y, Huang J, et al
   Epigenetic clocks in neurodegenerative diseases: a systematic review.
   J Neurol Neurosurg Psychiatry. 2023;94:1064-1070.
   PubMed     Abstract available
   
   
   November 2023
10. GOLDBERG TE, Lee S, Devanand DP, Schneider LS, et al
    Comparison of relative change with effect size metrics in Alzheimer's disease clinical trials.
    J Neurol Neurosurg Psychiatry. 2023 Nov 18:jnnp-2023-331941.
    PubMed     Abstract available
    
    
    October 2023
11. GRAHAM N, Zimmerman K, Heslegrave AJ, Keshavan A, et al
    Alzheimer's disease marker phospho-tau181 is not elevated in the first year after moderate-to-severe TBI.
    J Neurol Neurosurg Psychiatry. 2023 Oct 13:jnnp-2023-331854.
    PubMed     Abstract available
    
    
    
12. LI H, Tan CC, Tan L, Xu W, et al
    Predictors of cognitive deterioration in subjective cognitive decline: evidence from longitudinal studies and implications for SCD-plus criteria.
    J Neurol Neurosurg Psychiatry. 2023;94:844-854.
    PubMed     Abstract available
    
    
    September 2023
13. SHINOHARA M, Gheni G, Hitomi J, Bu G, et al
    APOE genotypes modify the obesity paradox in dementia.
    J Neurol Neurosurg Psychiatry. 2023;94:670-680.
    PubMed     Abstract available
    
    
    
14. DUNNE R, Coulthard E
    Tipping the scales towards routine APOE genotyping.
    J Neurol Neurosurg Psychiatry. 2023;94:669.
    PubMed    
    
    
    August 2023
15. CHUN MY, Jang H, Kim SJ, Park YH, et al
    Emerging role of vascular burden in AT(N) classification in individuals with Alzheimer's and concomitant cerebrovascular burdens.
    J Neurol Neurosurg Psychiatry. 2023 Aug 9:jnnp-2023-331603.
    PubMed     Abstract available
    
    
    June 2023
16. SU WM, Gu XJ, Dou M, Duan QQ, et al
    Systematic druggable genome-wide Mendelian randomisation identifies therapeutic targets for Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2023 Jun 22:jnnp-2023-331142.
    PubMed     Abstract available
    
    
    
17. COULTHARD E, Hosseini AA
    Blood biomarkers: ready for clinical practice?
    J Neurol Neurosurg Psychiatry. 2023;94:409-410.
    PubMed    
    
    
    
18. LEHMANN S, Schraen-Maschke S, Vidal JS, Delaby C, et al
    Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function.
    J Neurol Neurosurg Psychiatry. 2023;94:411-419.
    PubMed     Abstract available
    
    
    April 2023
19. DAI L, Gao F, Wang Q, Lv X, et al
    Molecules of senescent glial cells differentiate Alzheimer's disease from ageing.
    J Neurol Neurosurg Psychiatry. 2023 Apr 3:jnnp-2022-330743.
    PubMed     Abstract available
    
    
    
20. ALTOMARE D, Stampacchia S, Ribaldi F, Tomczyk S, et al
    Plasma biomarkers for Alzheimer's disease: a field-test in a memory clinic.
    J Neurol Neurosurg Psychiatry. 2023 Apr 3:jnnp-2022-330619.
    PubMed     Abstract available
    
    
    
21. VACCHIANO V, Mastrangelo A, Zenesini C, Baiardi S, et al
    Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis.
    J Neurol Neurosurg Psychiatry. 2023 Apr 3:jnnp-2022-330709.
    PubMed     Abstract available
    
    
    
22. VAN 'T HOOFT JJ, Pelkmans W, Tomassen J, Smits C, et al
    Distinct disease mechanisms may underlie cognitive decline related to hearing loss in different age groups.
    J Neurol Neurosurg Psychiatry. 2023;94:314-320.
    PubMed     Abstract available
    
    
    February 2023
23. HAZAN J, Wing M, Liu KY, Reeves S, et al
    Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2023;94:113-120.
    PubMed     Abstract available
    
    
    January 2023
24. JIANG Y, Wan M, Xiao X, Lin Z, et al
    GSN gene frameshift mutations in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2023 Jan 17:jnnp-2022-330465.
    PubMed     Abstract available
    
    
    December 2022
25. O'CONNOR A, Rice H, Barnes J, Ryan NS, et al
    First presentation with neuropsychiatric symptoms in autosomal dominant Alzheimer's disease: the Dominantly Inherited Alzheimer's Network Study.
    J Neurol Neurosurg Psychiatry. 2022 Dec 15:jnnp-2022-329843.
    PubMed    
    
    
    
26. HUSAIN M
    Noradrenergic therapies for apathy in Alzheimer's disease?
    J Neurol Neurosurg Psychiatry. 2022 Dec 5:jnnp-2022-330824.
    PubMed    
    
    
    November 2022
27. AYTON S, Janelidze S, Kalinowski P, Palmqvist S, et al
    CSF ferritin in the clinicopathological progression of Alzheimer's disease and associations with APOE and inflammation biomarkers.
    J Neurol Neurosurg Psychiatry. 2022 Nov 10. pii: jnnp-2022-330052.
    PubMed     Abstract available
    
    
    August 2022
28. HALBGEBAUER S, Steinacker P, Hengge S, Oeckl P, et al
    CSF levels of SNAP-25 are increased early in Creutzfeldt-Jakob and Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2022 Aug 22. pii: jnnp-2021-328646.
    PubMed     Abstract available
    
    
    
29. O'CONNOR A, Abel E, Benedet AL, Poole T, et al
    Plasma GFAP in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study.
    J Neurol Neurosurg Psychiatry. 2022 Aug 10. pii: jnnp-2022-329663.
    PubMed    
    
    
    
30. BARBA L, Abu Rumeileh S, Bellomo G, Paolini Paoletti F, et al
    Cerebrospinal fluid beta-synuclein as a synaptic biomarker for preclinical Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2022 Aug 9. pii: jnnp-2022-329124.
    PubMed     Abstract available
    
    
    July 2022
31. DAVID MCB, Del Giovane M, Liu KY, Gostick B, et al
    Cognitive and neuropsychiatric effects of noradrenergic treatment in Alzheimer's disease: systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2022 Jul 5. pii: jnnp-2022-329136.
    PubMed     Abstract available
    
    
    June 2022
32. OVERMAN MJ, Drummond N, Butler CR, Ahmed S, et al
    Tracking the clinical progression of posterior cortical atrophy: implications for post-diagnostic and therapeutic interventions.
    J Neurol Neurosurg Psychiatry. 2022;93:683-684.
    PubMed    
    
    
    
33. PARNETTI L, Paolini Paoletti F, Gaetani L
    Blood biomarkers may distinguish among dementia disorders.
    J Neurol Neurosurg Psychiatry. 2022;93:571.
    PubMed    
    
    
    April 2022
34. OECKL P, Anderl-Straub S, Von Arnim CAF, Baldeiras I, et al
    Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion.
    J Neurol Neurosurg Psychiatry. 2022 Apr 27. pii: jnnp-2021-328547.
    PubMed     Abstract available
    
    
    March 2022
35. CHENG L, Li W, Chen Y, Lin Y, et al
    Plasma Abeta as a biomarker for predicting Abeta-PET status in Alzheimer's diseasea systematic review with meta-analysis.
    J Neurol Neurosurg Psychiatry. 2022 Mar 3. pii: jnnp-2021-327864.
    PubMed     Abstract available
    
    
    
36. KONCZ R, Thalamuthu A, Wen W, Catts VS, et al
    The heritability of amyloid burden in older adults: the Older Australian Twins Study.
    J Neurol Neurosurg Psychiatry. 2022;93:303-308.
    PubMed     Abstract available
    
    
    February 2022
37. LAGARDE J, Olivieri P, Tonietto M, Tissot C, et al
    Tau-PET imaging predicts cognitive decline and brain atrophy progression in early Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2022 Feb 28. pii: jnnp-2021-328623.
    PubMed     Abstract available
    
    
    January 2022
38. CHOULIARAS L, Thomas A, Malpetti M, Donaghy P, et al
    Differential levels of plasma biomarkers of neurodegeneration in Lewy body dementia, Alzheimer's disease, frontotemporal dementia and progressive supranuclear palsy.
    J Neurol Neurosurg Psychiatry. 2022 Jan 25. pii: jnnp-2021-327788.
    PubMed     Abstract available
    
    
    
39. HALBGEBAUER S, Steinacker P, Verde F, Weishaupt J, et al
    Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS.
    J Neurol Neurosurg Psychiatry. 2022;93:68-74.
    PubMed     Abstract available
    
    
    November 2021
40. ZHOU D, Li A, Li X, Zhuang W, et al
    Effects of 40 Hz transcranial alternating current stimulation (tACS) on cognitive functions of patients with Alzheimer's disease: a randomised, double-blind, sham-controlled clinical trial.
    J Neurol Neurosurg Psychiatry. 2021 Nov 11. pii: jnnp-2021-326885.
    PubMed    
    
    
    
41. ALCOLEA D, Delaby C, Munoz L, Torres S, et al
    Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.
    J Neurol Neurosurg Psychiatry. 2021;92:1206-1214.
    PubMed     Abstract available
    
    
    September 2021
42. CHONG JR, Ashton NJ, Karikari TK, Tanaka T, et al
    Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances.
    J Neurol Neurosurg Psychiatry. 2021 Sep 11. pii: jnnp-2021-327370.
    PubMed     Abstract available
    
    
    June 2021
43. RAUCHMANN BS, Schneider-Axmann T, Perneczky R
    Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Abeta-PET and cognition.
    J Neurol Neurosurg Psychiatry. 2021 Jun 29. pii: jnnp-2020-325537.
    PubMed     Abstract available
    
    
    
44. CHEUNG CY, Mok V, Foster PJ, Trucco E, et al
    Retinal imaging in Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2021 Jun 9. pii: jnnp-2020-325347.
    PubMed     Abstract available
    
    
    April 2021
45. SINGLETON E, Hansson O, Pijnenburg YAL, La Joie R, et al
    Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2021 Apr 13. pii: jnnp-2020-325497.
    PubMed     Abstract available
    
    
    February 2021
46. OLIVEIRA FPM, Walker Z, Walker RWH, Attems J, et al
    (123)I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease: a new quantitative analysis of autopsy confirmed cases.
    J Neurol Neurosurg Psychiatry. 2021 Feb 4. pii: jnnp-2020-324606.
    PubMed     Abstract available
    
    
    December 2020
47. HALBGEBAUER S, Oeckl P, Steinacker P, Yilmazer-Hanke D, et al
    Beta-synuclein in cerebrospinal fluid as an early diagnostic marker of Alzheimer's disease.
    J Neurol Neurosurg Psychiatry. 2020 Dec 30. pii: jnnp-2020-324306.
    PubMed     Abstract available
    
    
    
48. FULLGRABE C
    When hearing loss masquerades as cognitive decline.
    J Neurol Neurosurg Psychiatry. 2020;91:1248.
    PubMed    
    
    
    November 2020
49. KEIR LHM, Breen DP
    REM sleep behaviour disorder in patients without synucleinopathy.
    J Neurol Neurosurg Psychiatry. 2020;91:1239-1240.
    PubMed    
    
    
    October 2020
50. CHU CS, Li CT, Brunoni AR, Yang FC, et al
    Cognitive effects and acceptability of non-invasive brain stimulation on Alzheimer's disease and mild cognitive impairment: a component network meta-analysis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 28. pii: jnnp-2020-323870.
    PubMed     Abstract available
    
    
    
51. LU L, Zheng X, Wang S, Tang C, et al
    Anti-Abeta agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
    J Neurol Neurosurg Psychiatry. 2020 Oct 12. pii: jnnp-2020-323497.
    PubMed     Abstract available
    
    
    
52. KOH W, Lim L, Low A, Wong B, et al
    Development and validation of a brief visual based cognitive screening tool for dementia: the Visual Cognitive Assessment Test short-form (VCAT-S).
    J Neurol Neurosurg Psychiatry. 2020;91:1122-1123.
    PubMed    
    
    
    September 2020
53. AGIN A, Blanc F, Bousiges O, Villette C, et al
    Environmental exposure to phthalates and dementia with Lewy bodies: contribution of metabolomics.
    J Neurol Neurosurg Psychiatry. 2020;91:968-974.
    PubMed     Abstract available
    
    
    
54. BENUSSI A, Karikari TK, Ashton N, Gazzina S, et al
    Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration.
    J Neurol Neurosurg Psychiatry. 2020;91:960-967.
    PubMed     Abstract available
    
    
    May 2020
55. CHEN S, Honda T, Ohara T, Hata J, et al
    Serum homocysteine and risk of dementia in Japan.
    J Neurol Neurosurg Psychiatry. 2020;91:540-546.
    PubMed     Abstract available
    
    
    
56. SENOVA S, Fomenko A, Gondard E, Lozano AM, et al
    Anatomy and function of the fornix in the context of its potential as a therapeutic target.
    J Neurol Neurosurg Psychiatry. 2020;91:547-559.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.